Antihypertensive medicine sales in Belgium show a steady incremental pattern from 2024 to 2028, increasing from $3.5 per capita in 2024 to $3.7 per capita in 2028. The year-on-year growth rate continues to stay around 2.86% between 2024 and 2025, then remains constant through 2026 and 2027 before slightly increasing by 2.78% in 2028. Comparing the last two years, the markets have remained stable with minor increases reflecting sustained consumption. Over the last five years, the CAGR stands at approximately 1.13%, indicating modest average growth annually.
Future trends to watch for include the potential for new antihypertensive drugs entering the market, shifts in healthcare policies, increased prevalence of hypertension in an aging population, and advancements in personalized medicine which may impact sales volume and value. These factors could lead to more dynamic market developments beyond the steady growth observed in recent years.
